Home News Content

Abbey plans to acquire AI pharmaceutical company Landos Biopharma for over $200 million

zipperfly
3293 0 0

Recently, Abbott announced a final agreement with AI pharmaceutical company Landos Biopharma to acquire Landos for $212.5 million. The transaction is expected to be completed in the second quarter of 2024, but must meet customary transaction conditions, including approval from Landos shareholders. It is reported that the main experimental drug of Landos, NX-13, is a potential FIC oral NLRX1 agonist used for the treatment of ulcerative colitis, and it has entered clinical phase II.
Logomoney.com is an information publishing platform that only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

zipperfly
  • Follower

    0

  • Follow

    0

  • Article

    0